Latest news with #TilrayBrands
Globe and Mail
2 days ago
- Entertainment
- Globe and Mail
Breckenridge Distillery Unveils Limited-Edition Collectors Art Series Collaboration with Renowned Artist Miles Toland
BRECKENRIDGE, Colo., July 01, 2025 (GLOBE NEWSWIRE) -- Breckenridge Distillery, one of the most-awarded craft distilleries in the U.S., and a craft spirits brand by Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), proudly announces the fifth edition of its acclaimed Collectors Art Series. This year, the distillery partnered with muralist and painter Miles Toland to create a breathtaking label and mural as part of its limited release, the Breckenridge Calvados Cask Finish. Born in Santa Fe, New Mexico, and currently based in Spokane, Washington, Toland is known for his immersive murals and studio work that explore the liminal realms between sleep and wakefulness. His art blends geometric patterns and natural elements to express the spiritual connection between humanity and the unknown. In this edition of the Collectors Art Series, his design captures a transcendent moment in nature—where a figure, surrounded by Colorado's Rocky Mountains and lark buntings, dissolves into a mandala of harmony, balance, and unity. 'Blending is everything in my paintings,' says Toland. 'Just like whiskey, it's about creating bridges—between shadow and light, between form and formlessness. To have my work featured on a bottle of whiskey is an exciting fusion of two art forms that celebrate complexity and craftsmanship.' The label design will appear on the Breckenridge Calvados Cask Finish, bottled at 95 proof / 47.5% ABV. This limited release continues the tradition of the Distillery's artful cask finishes, offering rich aromas of freshly peeled red apples with warm oak and creamy vanilla and a hint of cinnamon spice on the nose, and a smooth entry of caramel, baked apple, and vanilla with layers of sweet oak and peppery spice on the palate. The finish lingers with a comforting touch of cinnamon. As with past editions, a donation of $5 per bottle sold will benefit Keep RiNo Wild (KRW), a 501(c)(3) whose mission is to provide and advocate for permanent, affordable community creative space within the district, to support and bolster the artist community which is here, as well as provide educational programming, events, classes and experiences for all ages, backgrounds and socio-economic groups. 'Miles' work dives into the mystical and unseen, and that mirrors the sensory journey we try to create with our whiskeys,' said Bryan Nolt, founder of Breckenridge Distillery. 'This collaboration is another chapter in our ongoing celebration of blending—color, spirit, and culture.' Breckenridge Collectors Art Series releases have earned numerous accolades, including 2023 Best Blended LTD Release and 2020 Icons of Whisky's Campaign Innovator of the Year at the World Whiskies Awards, along with Gold and Double Gold medals at the San Francisco World Spirits Competition. Breckenridge Collectors Art Series 5 will be available starting July 1, exclusively at Breckenridge Distillery and the Main Street Tasting Room in Breckenridge, Colorado, for $125. You can visit Toland's latest mural behind Number Thirty Eight in Denver, Colorado at 3560 Chestnut Pl, Denver, CO 80216, along with the 2024 mural by Abby Wren and 2022 mural by Alexandrea Pangburn. For more information about Breckenridge Distillery, visit Follow Breckenridge on Instagram @breckdistillery and become a fan at Age 21+. Always enjoy responsibly. To learn more about Miles Toland, follow him on Instagram @milestoland and visit About Breckenridge Distillery Founded in Colorado in 2008, Breckenridge Distillery is the 'World's Highest Distillery,' and is best known for its award-winning blended bourbon whiskey, a high-rye mash American-style whiskey. One of the most highly awarded distilleries in the U.S., the Breckenridge Distillery is proudly a 3x Icons of Whisky and 10x winner of Best American Blended winner at the World Whiskies Awards by Whisky Magazine and a 4x winner of Colorado Distillery of the Year by the New York International Spirits Competition. Most recently, Breckenridge Port Cask Finish was named World's Best Finished Bourbon at the 2024 World Whiskies Awards, joining Breckenridge High Proof, named World's Best Blended Whiskey and Breckenridge Gin, named World's Best Compound Gin at the World Gin Awards by Gin Magazine. Breckenridge spirits have been awarded 6 Double Golds at the San Francisco World Spirits Competition. The Breckenridge Distillery is more than award-winning spirits, offering an immersive guest experience. Named as one of the country's Top Visitor Attractions by Whisky Magazine, guests can dine at their award-winning restaurant, enjoy show-stopping cocktails, learn about their highly awarded spirits with an in-depth tasting, and get an inside look at their active production facility. New to the distillery, guests have the opportunity to blend their own whiskey as they learn the inner workings of whiskey production. Breckenridge Distillery is a subsidiary of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company inspiring and empowering the worldwide community to live their very best life. To learn more about Breckenridge Distillery, visit Keep up with Breckenridge Distillery on Instagram by following @breckdistillery and become a fan at For more information about Tilray Brands, visit and follow @tilray on Instagram, Twitter, Facebook, and LinkedIn. Forward-Looking Statements Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, 'forward-looking statements') under Canadian and U.S. securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the 'safe harbor' created by those sections and other applicable laws. Forward-looking statements can be identified by words such as 'forecast,' 'future,' 'should,' 'could,' 'enable,' 'potential,' 'contemplate,' 'believe,' 'anticipate,' 'estimate,' 'plan,' 'expect,' 'intend,' 'may,' 'project,' 'will,' 'would' and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws. For further information, please contact Photos accompanying this announcement are available at:
Yahoo
5 days ago
- Business
- Yahoo
Tilray Brands, Inc. (TLRY) Stock Declines While Market Improves: Some Information for Investors
Tilray Brands, Inc. (TLRY) closed the most recent trading day at $0.40, moving -2.84% from the previous trading session. The stock fell short of the S&P 500, which registered a gain of 0.52% for the day. Meanwhile, the Dow gained 1%, and the Nasdaq, a tech-heavy index, added 0.52%. The company's shares have seen a decrease of 11.24% over the last month, not keeping up with the Medical sector's gain of 3.5% and the S&P 500's gain of 5.95%. Analysts and investors alike will be keeping a close eye on the performance of Tilray Brands, Inc. in its upcoming earnings disclosure. On that day, Tilray Brands, Inc. is projected to report earnings of -$0.03 per share, which would represent year-over-year growth of 25%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $254.8 million, up 10.84% from the year-ago period. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$1.01 per share and revenue of $850.75 million, indicating changes of -206.06% and 0%, respectively, compared to the previous year. Investors should also pay attention to any latest changes in analyst estimates for Tilray Brands, Inc. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability. Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Currently, Tilray Brands, Inc. is carrying a Zacks Rank of #3 (Hold). The Medical - Products industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 164, placing it within the bottom 34% of over 250 industries. The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Keep in mind to rely on to watch all these stock-impacting metrics, and more, in the succeeding trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Tilray Brands, Inc. (TLRY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
The Market Online
24-06-2025
- Business
- The Market Online
Tilray sets medical cannabis milestone in Italy
Tilray Medical, a division of Tilray Brands (TSX:TLRY), has become the first company to receive Italian authorization to distribute medical cannabis flower for therapeutic use Tilray is a global consumer packaged goods company active in cannabis, beverage, wellness and entertainment Tilray stock has given back 78.17 per cent year-over-year and 97.46 per cent since 2021 Tilray Medical, a division of major cannabis player Tilray Brands (TSX:TLRY), has become the first company to receive authorization from Italy's Ministero della Salute to distribute medical cannabis flower for therapeutic use. Tilray Medical, operating through wholly-owned subsidiary, FL Group, will introduce three new medical cannabis flower varieties to Italy beginning in June, which will be available for distribution through pharmacies across the country. They are: Tilray THC 25%. Tilray THC 18%. Tilray THC 9% / CBD 9%. The approval complements Tilray's existing presence in Italy, initially announced in May 2023, as well as its leading position in the European market, including operations in Germany, Portugal, Poland and the United Kingdom. Leadership insights 'This milestone underscores the vital role of medical cannabis as a therapeutic medicine for patients in need, supporting their health and well-being. We are proud to expand our medical cannabis portfolio in Italy with the introduction of our Tilray Medical high-quality, EU-GMP certified medical cannabis products that uphold the highest standards in patient care,' Denise Faltischek, Tilray Brands' chief strategy officer and head of international, said in a statement. 'We extend our gratitude to the Ministero della Salute for their trust in Tilray Medical and for providing the necessary regulatory framework to ensure access to safe, consistent and reliable cannabinoid-based therapies. Together, we are advancing healthcare and patient wellness through innovation and collaboration.' About Tilray Brands Tilray is a global consumer packaged goods company active in cannabis, beverage, wellness and entertainment. The company's platform includes more than 40 brands spanning presences in more than 20 countries. Tilray stock (TSX:TLRY) last traded at C$0.50. The stock has given back 78.17 per cent year-over-year and 97.46 per cent since 2021. Join the discussion: Find out what investors are saying about this cannabis stock's expansion in Italy on the Tilray Brands Inc. Bullboard, and make sure to check out the rest of Stockhouse's stock forums and message boards. The material provided in this podcast is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
Yahoo
24-06-2025
- Business
- Yahoo
Tilray Medical Receives Italy's First Authorization from the Ministry of Health to Distribute Medical Cannabis Flower for Therapeutic Use
SAVONA, Italy, June 24, 2025 (GLOBE NEWSWIRE) -- Tilray Medical ('Tilray'), a division of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY) and a global leader in medicinal cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, today announced a significant milestone in its European expansion with the introduction of three new medical cannabis flower varieties in Italy. Through its wholly-owned subsidiary, FL Group, Tilray has become the first company in Italy to receive official authorization from the Ministero della Salute (Italian Ministry of Health) to import and distribute proprietary Tilray Medical-branded medical cannabis flower for therapeutic use. Beginning this month, the following Tilray Medical products are approved for therapeutic use in Italy and available for distribution through pharmacies across Italy: Tilray THC 25% Tilray THC 18% Tilray THC 9% / CBD 9% Denise Faltischek, Chief Strategy Officer and Head of International at Tilray Brands, stated, 'This milestone underscores the vital role of medical cannabis as a therapeutic medicine for patients in need, supporting their health and well-being. We are proud to expand our medical cannabis portfolio in Italy with the introduction of our Tilray Medical high-quality, EU-GMP certified medical cannabis products that uphold the highest standards in patient care. We extend our gratitude to the Ministero della Salute for their trust in Tilray Medical and for providing the necessary regulatory framework to ensure access to safe, consistent and reliable cannabinoid-based therapies. Together, we are advancing healthcare and patient wellness through innovation and collaboration.' Tilray continues to lead the European medical cannabis market with operations in Germany, Italy, Portugal, Poland and the United Kingdom, offering a broad portfolio of EU-GMP certified medical cannabis products. About Tilray Medical Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray Medical, Broken Coast, Redecan, Good Supply and Navcora. Tilray Medical grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first EU-GMP certified cannabis production facilities in Portugal and Germany. Today, Tilray Medical is a leading supplier of medical cannabis with a portfolio of brands and products designed to meet the needs of our patients worldwide. For further information on Tilray Medical, visit Tilray Medical Europe, Tilray Medical Canada, and Tilray Medical Australia-New Zealand. About Tilray Brands Tilray Brands, Inc. ('Tilray') (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, New Zealand and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. Tilray's mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray's unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages. For more information on how we are elevating lives through moments of connection, visit and follow @Tilray on all social platforms. Forward-Looking Statements Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, 'forward-looking statements') under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the 'safe harbor' created by those sections and other applicable laws. Forward-looking statements can be identified by words such as 'forecast,' 'future,' 'should,' 'could,' 'enable,' 'potential,' 'contemplate,' 'believe,' 'anticipate,' 'estimate,' 'plan,' 'expect,' 'intend,' 'may,' 'project,' 'will,' 'would' and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company's ability to commercialize new and innovative products worldwide. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws. For further information:Media: news@ Relations: investors@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11-06-2025
- Business
- Yahoo
Tilray Brands pauses stock-split plan despite shareholder approval
Beverages-to-cannabis business Tilray Brands has 'paused' plans to reduce the number of market-traded shares as the company assesses its options. While Nasdaq-listed Tilray Brands said in a statement yesterday (10 June) that the reverse stock split has been approved by its shareholders, the North American business is holding back from proceeding. The beers and energy drinks maker said it was 'exploring all options related to timing of the reverse split as it evaluates timing and stock price'. Tilray Brands' shares have dived since the company went public in 2018 and were trading at 42 US cents yesterday, compared to the IPO price of $17. One of the reasons cited yesterday by New York-headquartered Tilray Brands for the stock split was 'ensuring compliance' with Nasdaq listing rules, which require traded companies to maintain a minimum bid price of $1. Media speculation suggests the reason for the shares' collapse is linked more with the US cannabis industry, where some states have legalised its use for medicinal and/or recreational purposes but it is not legal at the federal level. The state of Texas is now moving to ban the use of THC products, while there is some doubt as to whether President Donald Trump will legalise pot. Cannabis use is legal in Canada, where Tilray Brands operates out of Leamington in Ontario. Bloomberg reported that the pessimism around cannabis use is evident in what the news agency said was the largest exchange-traded fund tracking the legal weed industry. The AdvisorShares Pure US Cannabis ETF, traded at around $2.37, down 96% from the closing high of $55.05 in February 2021, Bloomberg said. It quoted Roth Capital Partners analyst Bill Kirk as saying in an interview: 'There's been this carrot that's been dangling in front of this industry for so long, and it's been a mirage. If the carrot's there, it's rotten at this point. No one's chasing it anymore, no one believes it's going to come to pass.' Tilray Brands, which owns a slate of breweries such as Atwater, Alpine and Hop Valley, made no mention of the cannabis industry yesterday as it seeks to purse a reverse stock split in a range of 1 for ten to 1 for 20 shares. 'Upon implementation of the reverse stock split, the company believes it would be well positioned for strategic opportunities and acquisitions given its strong balance sheet,' said the statement. As well as complying with Nasdaq listing rules, Tilray Brands said the split would better align the number of outstanding shares with 'companies of its size and scope' and make the business 'more attractive to institutional shareholders'. However, Bloomberg pointed out that Tilray Brands had a market capitalisation of almost $20bn in 2018 when it went public but that is now less than $500m. Meanwhile, Tilray Brands cut its sales forecast for fiscal 2025 in April, citing 'adjustments for constant currency and the impacts of the strategic initiatives and SKU rationalisation'. In January, the business announced plans to cut more than 300 SKUs as part of a wider programme dubbed Project 420 through which Tilray Brands was looking to find synergies to boost the profitability of its drinks division. The Hi*Ball Energy drinks producer lowered its revenue guidance to $850m-$900m, from $950m to $1bn previously. "Tilray Brands pauses stock-split plan despite shareholder approval" was originally created and published by Just Drinks, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
